Observational Safety Study of Etanercept (Enbrel) for Treatment of Psoriasis

Amgen

Status: Completed

Conditions: Psoriasis

Treatments: Drug: Etanercept

Study type: Observational

Funder types: Industry

Identifiers

NCT00322439

20040210

Details and patient eligibility

About

This is an observational safety study tracking psoriasis patients on etanercept (Enbrel) for 5 years.

Full description

This is a prospective, multi-center, observational surveillance registry to evaluate data on the long-term safety of etanercept (Enbrel) use in the treatment of psoriasis.

Enrollment: 2,511 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with plaque psoriasis

Exclusion criteria

• Prior exposure to any tumor necrosis factor (TNF)-inhibitor
• Patients for whom Enbrel is contraindicated
• Patients currently enrolled in or has not yet completed at least 30 days since ending other investigational drug study.

Trial design

2,511 participants in 1 patient group

Etanercept

Description:

Participants received etanercept (Enbrel) treatment at the dose and regimen determined by the investigator and were evaluated for up to 5 years at 6-month intervals. During this period, participants may have discontinued etanercept therapy, may have switched to another anti-psoriatic therapy, may have used etanercept in combination with other anti-psoriatic therapies, or may have discontinued any or all antipsoriatic treatments.

Treatment:

Drug: Etanercept